Splet23. mar. 2024 · Adding trabectedin to PLD significantly prolonged OS and PFS in BRCA1/2 patients with advanced epithelial OC, according to a prespecified phase 3 subgroup analysis. SpletOverall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer. 2024 Aug 1;125(15):2610-2620. Epub 2024 Jun 7. link to original article link to PMC article PubMed
The Characteristics of magnetic resonance imaging and ...
Splet30. mar. 2024 · Trabectedin was an interesting compound to combine with radiotherapy in myxoid liposarcoma for several reasons. First, trabectedin is a DNA minor groove … Splet11. mar. 2024 · Myxoid liposarcoma (ML) exhibits a special sensitivity to trabectedin (T) and radiation therapy (RT). Preclinical data suggest a synergistic effect. We aimed to … targashians
Liposarcoma - by Brian Schulte - The Sarcoma Letter
Splet14. apr. 2024 · The endpoint for trabectedin for patients with liposarcoma and leiomyosarcoma was progression free survival. 14. Conclusions. Liposarcoma, even … Splet06. okt. 2024 · A post hoc analysis of the pivotal phase II study of trabectedin in patients with advanced liposarcoma or leiomyosarcoma identified a higher number of median cycles (six vs three) and a greater proportion of patients receiving six or more cycles (53.2 vs 36.6%) during second- versus later-line use . SpletRecently, trabectedin has been approved by the US Food and Drug Administration (FDA) based on the result of an open-label, randomized (2:1) Phase III trial of trabectedin (n=345) vs dacarbazine (n=173) in patients with metastatic liposarcoma or leiomyosarcoma. 46 In the final analysis of PFS, trabectedin administration resulted in a 45% ... targa snip